scholarly journals Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study

2006 ◽  
Vol 154 (1) ◽  
pp. 101-107 ◽  
Author(s):  
Kati Pentti ◽  
Risto Honkanen ◽  
Marjo T Tuppurainen ◽  
Lorenzo Sandini ◽  
Heikki Kröger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factor ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Cancer Mortality ◽  
Hormone Replacement ◽  
Breast Cancer Mortality ◽  
Prevention Study ◽  
Osteoporosis Risk

Objectives: To analyze prospectively the association between hormone replacement therapy (HRT) and mortality in women before old age. Design and methods: A group of 11 667 women (91% of the age cohort of the area) aged 52–62 years from the population-based Kuopio Osteoporosis Risk Factor and Prevention Study were followed for 7 years in 1994–2001. Information about HRT use and health events was obtained from two repeated questionnaires in 1989 and 1994. Information about deaths and causes of death from the follow-up period was obtained from the Statistics Finland. Cox’s proportional-hazards models were used to calculate risk of death related to the use of HRT. Results: At the start of follow-up, 2203 women had used HRT >5 years, 3945 women ≤5 years and 5519 women had never used it. During the follow-up, 361 deaths occurred. Compared with non-users of HRT, the adjusted hazard ratio (HR) of death from any cause was 1.05 (95% confidence interval (CI) 0.80–1.36) in women who used HRT ≤5 years and 1.06 (95% CI 0.78–1.46) in women who used HRT >5 years. The adjusted HR for coronary heart disease (CHD) mortality in women who used HRT ≤5 years was 0.79 (95% CI 0.36–1.73), and in women who used HRT >5 years, 2.16 (95% CI 0.93–4.98). For breast cancer mortality the adjusted HR for ≤5 years of HRT use was 0.96 (95% CI 0.32–2.82) and 2.62 (95% CI 0.98–7.00) for >5 years of HRT use. Conclusions: History of HRT use does not affect overall or CHD mortality in women. More than 5 years of HRT use may increase the risk of breast cancer mortality.

Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for ?healthy drug-user? effect

1993 ◽  
Vol 4 (4) ◽  
pp. 369-374 ◽  
Author(s):  
Jonathan Yuen ◽  
Ingemar Persson ◽  
Leif Bergkvist ◽  
Robert Hoover ◽  
Catherine Schairer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Drug User ◽  
Cancer Mortality ◽  
Hormone Replacement ◽  
Breast Cancer Mortality

scholarly journals Hormone replacement therapy in menopause as a risk factor for developing breast cancer

2014 ◽  
Vol 6 (3) ◽  
pp. 1302-1312
Author(s):  
Natasha Souto ◽  
Camila Moreira ◽  
Paulo Augusto Barros ◽  
Ana Fátima Fernandes ◽  
Míria Santos
Keyword(s):  
Breast Cancer ◽  
Risk Factor ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement

Mode of detection and breast cancer mortality by follow-up time and tumor characteristics among screened women in Cancer Prevention Study-II

2019 ◽  
Vol 177 (3) ◽  
pp. 679-689 ◽  
Author(s):  
Samantha Puvanesarajah ◽  
Susan M. Gapstur ◽  
Alpa V. Patel ◽  
Mark E. Sherman ◽  
W. Dana Flanders ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Prevention ◽  
Cancer Mortality ◽  
Breast Cancer Mortality ◽  
Tumor Characteristics ◽  
Prevention Study ◽  
Mode Of Detection

Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial

2013 ◽  
Vol 49 (1) ◽  
pp. 52-59 ◽  
Author(s):  
Mia Fahlén ◽  
Tommy Fornander ◽  
Hemming Johansson ◽  
Ulla Johansson ◽  
Lars-Erik Rutqvist ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Randomised Trial

Is there a role for hormone replacement therapy after breast cancer?

2005 ◽  
Vol 11 (4) ◽  
pp. 140-144 ◽  
Author(s):  
Kenny Kwan ◽  
Charlotte Ward ◽  
Jo Marsden
Keyword(s):  
Breast Cancer ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Early Stage ◽  
Hormone Replacement ◽  
Breast Cancer Mortality ◽  
Menopausal Status ◽  
Early Stage Disease ◽  
Estrogen Synthesis

Breast cancer is the most common female malignancy in the UK, with an overall lifetime risk of 1 in 9. Despite the high incidence, breast cancer mortality is decreasing. Approximately 40,000 women were diagnosed with breast cancer in England and Wales in 2000 but the majority will have normal or near-normal life expectancy. One of the main contributory factors to this marked improvement in survival over the last 20 years in women of all ages has been the more widespread use of systemic therapy in early-stage disease. For women with hormone-sensitive cancer, this involves adjuvant endocrine therapy that reduces estrogen synthesis (i.e. ovarian suppression in premenopausal women or aromatase inhibitors in postmenopausal women) or estrogen activity (the anti-estrogen tamoxifen, irrespective of menopausal status). Many women experience health and quality-of-life problems related to estrogen deficiency as a result, the commonest being vasomotor symptoms and vaginal dryness. This article summarizes and interprets key recent papers on the use of hormone replacement therapy (HRT) and selective serotonin reuptake inhibitors in breast cancer survivors. HRT may be safe in women with receptor-negative disease or receptor-positive cancers in the presence of tamoxifen. However, there is a dearth of useful alternatives.

Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up

2008 ◽  
Vol 196 (4) ◽  
pp. 505-511 ◽  
Author(s):  
Dara Christante ◽  
SuEllen Pommier ◽  
Jennifer Garreau ◽  
Patrick Muller ◽  
Brett LaFleur ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Cancer Survival ◽  
Hormone Replacement ◽  
Breast Cancer Survival

Hormone replacement therapy in menopause as a risk factor for developing breast cancer

2014 ◽  
Vol 6 (3) ◽  
pp. 1302-1312
Author(s):  
Natasha Firmino Souto ◽  
Camila Brasil Moreira ◽  
Paulo Augusto Soares Barros ◽  
Ana Fátima Carvalho Fernandes ◽  
Míria Conceição Lavinas Santos
Keyword(s):  
Breast Cancer ◽  
Risk Factor ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Cáncer De Mama

Objetivo: Analisar a produção científica envolvendo o uso da terapia de reposição hormonal no climatério como um fator de risco para desenvolvimento de câncer de mama. Método: Realizou-se uma revisão integrativa da literatura. Utilizamos as bases de dados BDENF, LILACS e SciELO. Identificamos 71 artigos, dos quais 24 compuseram nossa amostra. Resultados: Observamos que o Brasil foi o país com mais publicações e o idioma mais requisitado foi o português. Em relação à escolha do delineamento do estudo, 50% dos estudos possuíam abordagem metodológica do tipo qualitativa e o método de coleta de dados por meio de documentos foi o mais utilizado. Conclusão: A enfermagem como profissional da saúde deve orientar as mulheres em idade perimenopausa sobre os riscos e benefícios do uso da terapia de reposição hormonal a fim de auxiliá-las na adesão ou não a esse tratamento. 

Sign in / Sign up

Export Citation Format

Share Document